Sample budget: a first-in-human medical device trial in Latin America

Sample budget, not a quote. Every figure on this page is an illustrative scenario: a sample budget for a typical first-in-human (FIH) medical device trial in Latin America, built on stated assumptions. Real studies vary widely. It is not a quote, a fixed price, an offer or a commitment. Your budget depends on your protocol, device, country, sites and enrollment, and bioaccess® prepares it individually.

This page walks through an illustrative scenario: a line-by-line sample budget for a typical first-in-human (FIH) medical device trial in Latin America. It is built from the bioaccess® rate card (version 2026.17) and from the ranges in the FIH and early feasibility study (EFS) budgets we prepared in 2026, with sponsor details removed. Official fees come from each regulator's published schedule.

Assumptions behind these samples

  • Minimally invasive device: catheter-based, wearable or diagnostic device with a short procedure. Surgical implant: permanent implant placed in an operating room (OR) or cath lab, such as a valve, stent graft or neurostimulator, with anesthesia, a hospital stay and longer follow-up.
  • Subjects and sites: Sample A has 20 subjects; Sample B has 10. Each is shown at one site, with a two-site variant. About 30% screen failures are allowed for.
  • Duration: about 4 months of start-up, then enrollment at a planning pace of about 2.5 subjects per site per month (minimally invasive device) or 1.25 (surgical implant), with a 3-month minimum. Follow-up is 1 month (minimally invasive device, 30-day primary endpoint) or 6 months (surgical implant), then about 2 months of close-out and reporting.
  • Visit schedule: screening, procedure and protocol follow-up visits paid per subject to the site; an on-site interim monitoring visit about every 2 active months per site (at least 4) at the I.1 floor of $1,950 per day, plus one close-out visit per site at the F.3 floor of $2,250. Those fees are preparation, the day, and the report only. Travel time, travel expenses, remote monitoring (I.2), and approved hour overruns are scoped separately and are not inside the visit line.
  • Included: per-subject site payments at cost; site payment administration (K.1) at a flat $300 per active site-month ($150 in a month with no site invoice), not a percentage of grants; pass-throughs at cost (insurance, ethics and authority fees, freight, and the cost of travel) with no percentage handling fee on insurance, official fees or freight — a commercial vendor invoice that a coordination fee does not already cover is cost plus 8%, capped at $5,000 per invoice (C.16); medical monitor retainer; up to three serious adverse events; a clinical study report; and a 15% contingency on professional fees (N.1). Cash advances are not included in these totals.
  • Excluded: the EDC license, the device itself, core labs, and independent safety committees (DSMB, data safety monitoring board, or CEC, clinical events committee). Taxes and currency movements are also excluded.
  • Hourly consulting (quoted separately): not in these sample totals. Senior regulatory and first-in-human strategy is K.24 at $350/h, with travel time at $175/h. Ad-hoc medical writing is K.25 at $250/h. Standard regulatory ad-hoc work remains K.4 at $225/h, and project management remains K.5 at $150/h. A full local customization of the protocol and ICF remains K.11 ($24,000). These floors apply to agreements signed on or after 17 November 2026.
  • Travel coordination fee (quoted separately): not in these sample totals. On Work Orders executed on or after 18 November 2026, flights, lodging, pre-booked ground transport, meals and per diems that bioaccess® arranges or pays are billed at cost plus a 10% coordination fee (C.16(f)), with no minimum or maximum, as its own line. Travel never carries the 8% vendor fee, and travel the sponsor books itself carries no fee.
  • Costa Rica: the 3% CONIS levy is shown as a separate line under each sample table. Costa Rica is the only country in Latin America with such a levy.

Estimate a range for your study

Estimate a range for your study

The clinical trial calculator applies the same assumptions as the tables below. It returns a range, never a quote, and excludes the EDC license, the device, core labs, safety committees and taxes. Costa Rica includes the 3% levy.

Sample line-item budgets

Sample A: minimally invasive device, 20 subjects, one site

Line item (rate card code)Sample range (USD, US dollars)
Study design review, kick-off & site feasibility (A.1–A.3)~$38K
Site budget & contract negotiation (B.1–B.5)$9K – $13K
Ethics + regulatory submissions, translations, import permit (C.1–C.15)$53K – $61K
Legal representative / importer of record (C.14, monthly)$8K – $9K
Site initiation & training (D.1–D.6). D.3 site initiation is $2,900 per site for preparation, the on-site day, and the report. Travel is separate. This is not surgical proctoring.~$17K
TMF management (D.8, monthly per site)$5K – $6K
Device import & logistics (E.1–E.2)$4K – $13K
Off-site site management (G.2 $2,400 per enrolling site-month, G.3 $900 follow-up). Visit preparation and reports are not billed again here. No complexity percentage. G.0 is not included.$22K – $30K
On-site interim and close-out visits (I.1/J.31 $1,950 per day, F.3/J.32 $2,250 per close-out): preparation + day + report only. Travel, remote IMV (I.2 $1,125), and hour overruns are separate and not in this line.$10K – $12K
Safety and status reports (F.1, F.2, F.5, F.6). The upper figure adds the F.4 floor ($11,200) only when a separate local authority close-out remains required in writing after the CSR output map. The credit is set by that map, not by a fixed percentage.$22K – $33K
EDC build-out & training on the sponsor-licensed EDC (C.20–C.21; license not priced)$16K – $18K
Medical monitor retainer (H.2, $3,500/month, enrollment + follow-up)$32K – $39K
Serious adverse event handling (J.30, $3,500/event, 0–3 events)$0K – $11K
Clinical study report incl. statistical analysis plan and tables (feasibility tier CSR-T1/T1+, ≤30 subjects, ≤2 sites, single-arm). F.4 output-map credit applies to every CSR tier (CSR-T0 through CSR-T3, and CSR-F, CSR-I, and CSR-1a when scoped): before billing F.4, complete an output map; remove F.4 scope the CSR already includes; keep F.1/F.2; price only a separate local close-out that remains required in writing. The credit is set by the output map, not by a fixed percentage and not by substituting a CSR tier for F.4. The F.4 additional-site 50% rule is unchanged.$35K – $50K
Per-subject site payments (investigator, coordinator, procedures)$52K – $185K
Site payment administration (K.1: $300 per active site-month, $150 if that month has no site invoice; grants at cost, no percentage). Illustrated from enrollment through follow-up plus one reconciliation month.$2K – $3K
Pass-throughs at cost: trial insurance, ethics/authority fees, freight, and the cost of travel (the 10% travel coordination fee, C.16(f), is quoted separately and is not in this line)$20K – $48K
Third-party administration (C.16): $0 on this sample's pass-throughs, which are at cost or already covered by the shipment coordination fee. Other commercial invoices are cost + 8%, cap $5,000 per invoice. Not a percentage of site grants. The C.16(f) travel coordination fee is quoted separately and is not in this row.~$0K
Contingency reserve (N.1: 15% of professional fees; not a second advance on grants or pass-throughs)$41K – $52K
Sample total (about 15 months)$386K – $638K
Costa Rica only: add CONIS levy (3% of the total study budget, applied to the sample total)$12K – $19K
Sample total if run in Costa Rica$398K – $657K

Sample B: surgical implant, 10 subjects, one site, 6-month follow-up

Line item (rate card code)Sample range (USD, US dollars)
Study design review, kick-off & site feasibility (A.1–A.3)~$38K
Site budget & contract negotiation (B.1–B.5)$9K – $13K
Ethics + regulatory submissions, translations, import permit (C.1–C.15)$53K – $61K
Legal representative / importer of record (C.14, monthly)$11K – $12K
Site initiation & training (D.1–D.6). D.3 site initiation is $2,900 per site for preparation, the on-site day, and the report. Travel is separate. This is not surgical proctoring.~$17K
TMF management (D.8, monthly per site)$7K – $9K
Device import & logistics (E.1–E.2)$4K – $13K
Off-site site management (G.1 $4,200 per enrolling site-month, G.3 $900 follow-up). Visit preparation and reports are not billed again here. No complexity percentage. G.0 is not included.$41K – $54K
On-site interim and close-out visits (I.1/J.31 $1,950 per day, F.3/J.32 $2,250 per close-out): preparation + day + report only. Travel, remote IMV (I.2 $1,125), and hour overruns are separate and not in this line.$16K – $18K
Safety and status reports (F.1, F.2, F.5, F.6). The upper figure adds the F.4 floor ($11,200) only when a separate local authority close-out remains required in writing after the CSR output map. The credit is set by that map, not by a fixed percentage.$22K – $33K
EDC build-out & training on the sponsor-licensed EDC (C.20–C.21; license not priced)$16K – $18K
Medical monitor retainer (H.2, $3,500/month, enrollment + follow-up)$49K – $56K
Serious adverse event handling (J.30, $3,500/event, 0–3 events)$0K – $11K
Clinical study report incl. statistical analysis plan and tables (feasibility tier CSR-T1/T1+, ≤30 subjects, ≤2 sites, single-arm). F.4 output-map credit applies to every CSR tier (CSR-T0 through CSR-T3, and CSR-F, CSR-I, and CSR-1a when scoped): before billing F.4, complete an output map; remove F.4 scope the CSR already includes; keep F.1/F.2; price only a separate local close-out that remains required in writing. The credit is set by the output map, not by a fixed percentage and not by substituting a CSR tier for F.4. The F.4 additional-site 50% rule is unchanged.$35K – $50K
Per-subject site payments (investigator, coordinator, procedures, OR/facility)$321K – $605K
Site payment administration (K.1: $300 per active site-month, $150 if that month has no site invoice; grants at cost, no percentage). Illustrated from enrollment through follow-up plus one reconciliation month.$2K – $5K
Pass-throughs at cost: trial insurance, ethics/authority fees, freight, and the cost of travel (the 10% travel coordination fee, C.16(f), is quoted separately and is not in this line)$20K – $58K
Third-party administration (C.16): $0 on this sample's pass-throughs, which are at cost or already covered by the shipment coordination fee. Other commercial invoices are cost + 8%, cap $5,000 per invoice. Not a percentage of site grants. The C.16(f) travel coordination fee is quoted separately and is not in this row.~$0K
Contingency reserve (N.1: 15% of professional fees; not a second advance on grants or pass-throughs)$48K – $60K
Sample total (about 20 months)$710K – $1.13M
Costa Rica only: add CONIS levy (3% of the total study budget, applied to the sample total)$21K – $34K
Sample total if run in Costa Rica$731K – $1.16M

Two-site versions of the same samples come to about $444K–$732K (minimally invasive device) and $771K–$1.24M (surgical implant). A second site shortens enrollment but adds start-up, monitoring and site-management cost.

What drives the cost

  • Per-subject site payments. In our 2026 budgets these ran about $2.5K–$9K per subject for minimally invasive devices and $32K–$60K for surgical implants, which include operating room (OR) and facility time. This is the largest single swing.
  • Monitoring months. Off-site site management is billed per site-month at the card floors: $2,400 for a minimally invasive (non-surgical) enrolling site (G.2) and $4,200 for a surgical implant enrolling site (G.1). Follow-up months use $900 (G.3). Visit preparation and reports are not billed again on this line, and no blanket complexity percentage is added. Global program management (G.0, $4,500 per program-month) is a separate card line and is not in this sample. Slow enrollment costs money every month.
  • Follow-up length. Each extra month keeps a site, the legal representative and trial master file (TMF) management running.
  • Number of sites. Each site adds feasibility, contracting, an ethics submission, initiation and closure.
  • Third-party handling. Site grants are paid at cost. K.1 is a flat $300 per active site-month ($150 if that month has no site invoice), not a percentage of grants. Insurance, ethics and authority fees, freight already covered by the shipment coordination fee, and the cost of travel are at cost in this sample. Flights, lodging, pre-booked ground transport, meals and per diems that bioaccess® arranges or pays also carry a 10% coordination fee (C.16(f); no minimum or maximum) on Work Orders executed on or after 18 November 2026, quoted as its own line and not included in this sample total; sponsor-booked travel carries no fee. Any other commercial vendor invoice is cost plus 8%, capped at $5,000 per invoice (C.16). That administration fee is not applied to site grants.
  • Clinical study report (CSR). For a single-arm study of up to 30 subjects at one or two sites, the report (statistical analysis plan, data cleanup, tables, listings and figures, and the full report) is budgeted at $35K–$50K. Larger or randomized studies of about 31–75 subjects move to $55K–$75K. Whenever any CSR tier is in the budget (CSR-T0 through CSR-T3, and CSR-F, CSR-I, or CSR-1a when scoped), complete an F.4 output map before billing the study-closure report: remove closure scope the CSR already covers, keep F.1 and F.2, and price only a separate local close-out that remains required in writing. The credit is set by the output map, not by a fixed percentage and not by substituting a CSR tier for F.4. The F.4 additional-site 50% rule is unchanged. The upper end of the safety and status line is the F.4 floor ($11,200) only in that case.
  • CDISC. C.22b is $4,500 for a CDISC (SDTM/ADaM) readiness and gap review only. It is not submission-grade SDTM/ADaM/Define dataset delivery, and it is not included in this sample total. Full packages are quoted on scope under the CSR note ($25,000–$75,000+); that range is not a line in this sample.
  • Translation pages. When in-house translation is scoped, L.5-CT.1 is $0.19 per word, which is $47.50 per 250-word page, and L.5-CT.1a is $0.21 per word, which is $52.50 per 250-word page. Those page fees are not inside the C.1–C.15 line above.
  • Advances are not fees. Before first patient in, the sponsor may advance 10% of the forecast site-grant budget (K.1). Pass-through budgets over $100,000 may take an optional 10% advance (C.16(e)). Those advances fund planned costs. They are not added again on top of this sample, and the same invoice is never funded twice. Unused C.16(e) balances are reconciled at close-out. Unused K.1 balances are refunded at close-out. This sample's contingency is N.1, 15% of professional fees. N.1 and N.2 are unchanged from v2026.14.
  • Fast-track. A 15% premium on Section C start-up fees (MSA-FT) applies only when a site initiation visit is formally required inside the defined window. It is not built into this sample, and it is not a substitute for the site initiation visit.

Illustrative month-by-month timeline (Sample A)

Month 1Contract, kick-off, site feasibility and pre-study visits
Month 2Site budget and contract; translations; ethics dossier
Month 3Ethics and authority submissions; import permit
Month 4Approvals (planning target); device import; site initiation
Month 5–12Enrollment (planning pace ~2–3 subjects/month at one site); monitoring visits
Month 13Last subject follow-up (30-day primary endpoint, minimally invasive device example)
Month 14Database lock; close-out visit; statistics
Month 15Clinical study report; closure report to ethics/authority

An illustrative plan, not a commitment. Ethics committee and authority timelines are outside our control.

Official regulator and ethics fees

CountryPublished feeOfficial source
Costa RicaCONIS (national health research council) registration levy of 3% of the total study budget, the only levy of its kind in Latin America. Each accredited scientific ethics committee (CEC) sets its own review fee.Ley 9234, art. 60
El SalvadorSRS (health regulator) research project evaluation $2,040; annual renewal or substantial amendment $60. CNEIS (national ethics committee) initial review for international companies US$2,400.SRS fee schedule; CNEIS manual
PanamaCNBI (national bioethics committee) new protocol B/.1,500; amendment B/.800; additional site B/.500; annual renewal B/.800 (the balboa, B/., trades at par with the US dollar). Accredited institutional committees publish their own fees.CNBI PT-011A

Rate card prices are subject to change. Fees as published when this page was prepared. Check the official source before relying on them.

What's not included, and costs that often surface later

  • EDC license (we build and train on the sponsor's licensed system), the device itself, core labs, and independent safety committees (a data monitoring committee or clinical events committee).
  • Protocol authoring and medical writing beyond the CSR.
  • Hospital stays beyond the protocol and unscheduled visits. The sample allows for up to three serious adverse events (SAEs) at $3,500 each; more are billed per event.
  • Travel coordination fee: on Work Orders executed on or after 18 November 2026, 10% of the flights, lodging, pre-booked ground transport, meals and per diems that bioaccess® arranges or pays, quoted as its own line.
  • Screen failures above plan, extra pre-study visits, amendments, and months added by slow enrollment.
  • Taxes and currency movements on site contracts in local currency. (Costa Rica's 3% levy is shown separately under each sample table.)

Ask any CRO which of these are in its number before you compare totals.

Frequently asked questions

Is this a fixed price?

No. It is a sample budget of a typical first-in-human (FIH) medical device trial in Latin America. Actual budgets depend on protocol, device, country and sites, and are prepared individually.

Why are surgical implant studies so much more expensive?

Operating room (OR), hospital stay, imaging and longer follow-up are paid per subject to the hospital. In our 2026 proposals these ranged from about $32K to $60K per surgical implant subject, against roughly $2.5K to $9K for minimally invasive devices.

What official fees should I expect?

They are small next to site and monitoring costs. Examples: Panama's national bioethics committee charges B/.1,500 for a new protocol, and El Salvador's regulator charges $2,040 to evaluate a research project. Costa Rica is the exception: its national research council levies 3% of the total study budget. It is the only country in Latin America with such a levy.

Does running an FIH study in Latin America mean the device is FDA-approved?

No. Clinical data from a study abroad can support a later submission to the US Food and Drug Administration (FDA) if it meets FDA's criteria under 21 CFR (Code of Federal Regulations) 812.28, but no study approves a device. An investigational device remains investigational.

Is EDC included?

We build and train on an electronic data capture (EDC) system the sponsor licenses. The license itself is not included or priced.

How long might a study take?

For a minimally invasive device with 20 subjects at one site, about 15 months is a reasonable planning assumption from contract to clinical study report (CSR): about 4 months of start-up, 8 of enrollment, 1 of follow-up and 2 of close-out. These are planning assumptions, not commitments. Ethics and authority review times are outside our control.

Get a custom budget

Send us your protocol synopsis, and we'll prepare a fitted budget and timeline for Costa Rica, El Salvador, Panama or Chile.

Request a custom FIH budget

Glossary

  • CEC / CBI / CNBI / CNEIS: ethics committees (scientific-ethics committee; institutional bioethics committee; Panama's national bioethics committee; El Salvador's national health research ethics committee).
  • CONIS: Costa Rica's national health research council. SRS: El Salvador's health regulator.
  • Minimally invasive device: catheter-based, wearable or diagnostic, short procedure. Surgical implant: permanent implant placed in an OR or cath lab (e.g. valve, stent graft, neurostimulator), with anesthesia, hospital stay and longer follow-up.
  • CRO: contract research organization. CSR: clinical study report. EDC: electronic data capture. EFS: early feasibility study. FIH: first-in-human.
  • OR: operating room. SAE: serious adverse event. TMF: trial master file. FDA: US Food and Drug Administration. USD: US dollars. 21 CFR 812.28: the FDA rule on accepting clinical data from studies conducted outside the US.
Sample budget, not a quote. Every figure on this page is an illustrative scenario: a sample budget for a typical first-in-human (FIH) medical device trial in Latin America, built on stated assumptions. Real studies vary widely. It is not a quote, a fixed price, an offer or a commitment. Your budget depends on your protocol, device, country, sites and enrollment, and bioaccess® prepares it individually.